Autopsy report · NCT03169894
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
Cause of deathFunding or business
“Strategic reasons”
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 years 3 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Avalo Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Crohn Disease; Ulcerative Colitis
- Interventions
- MDGN-002
- Participants
- 8
- Sites
- 13
- Countries
- United States
Trials that died the same way
- Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
“for strategic reasons” - S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
“Strategic development reasons” - Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
“Due to strategic reasons” - Duodenal Exclusion for the Treatment of Type 2 Diabetes
“business reasons” - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
“Strategic considerations”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.